Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 6/20 | 0.38 |
| ▸ | F2 | P00734 | 3/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | NSD2 | O96028 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 2/20 | 0.33 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30002890 | 1.00 | RAPGEF4 (0.38) | RAPGEF4F2PRSS1PRSS2PRSS3 | |
| SCHEMBL29360228 | 0.82 | RAPGEF4 (0.37) | RAPGEF4F2PRSS1PRSS2PRSS3 | |
| SCHEMBL9103439 | 0.82 | RAPGEF4 (0.37) | RAPGEF4F2PRSS1PRSS2PRSS3 | |
| SCHEMBL30888383 | 0.81 | RAPGEF4 (0.36) | RAPGEF4F2PRSS1PRSS2PRSS3 | |
| SCHEMBL27225358 | 0.81 | RAPGEF4 (0.36) | RAPGEF4F2PRSS1PRSS2PRSS3 | |
| SCHEMBL16599611 | 0.81 | RAPGEF4 (0.36) | RAPGEF4F2PRSS1PRSS2PRSS3 | |
| SCHEMBL28628697 | 0.80 | RAPGEF4 (0.35) | RAPGEF4F2PRSS1PRSS2PRSS3 | |
| SCHEMBL28658591 | 0.80 | CYP1A2 (0.40) | RAPGEF4F2PRSS1PRSS2PRSS3 | |
| SCHEMBL31716978 | 0.79 | RAPGEF4 (0.39) | RAPGEF4F2PRSS1PRSS2PRSS3 | |
| SCHEMBL30888439 | 0.79 | RAPGEF4 (0.34) | RAPGEF4F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022214519-A1 | ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-10-13 | — | — | WO | disclosed |
| CN-109776522-B | Substituted heteroaryl compounds, compositions and uses thereof | 广东东阳光药业有限公司 | 2020-12-29 | — | — | CN | disclosed |
| EP-3710006-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | Sunshine Lake Pharma Co., Ltd. (CN) | 2020-09-23 | — | — | EP | disclosed |
| US-10683297-B2 | Substituted heteroaryl compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190152977-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | Northern Industrial Area, (CN) | 2019-05-23 | — | — | US | disclosed |
| EP-3126336-B1 | SUBSTITUTED FUSED HETEROCYCLES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI SA (FR) | 2018-12-05 | — | — | EP | disclosed |
| US-9758520-B2 | Substituted fused heterocycles as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | SANOFI (FR) | 2017-09-12 | — | — | US | disclosed |
| EP-3126336-A1 | SUBSTITUTED FUSED HETEROCYCLES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | Sanofi (FR) | 2017-02-08 | — | — | EP | disclosed |
| US-20170022198-A1 | SUBSTITUTED FUSED HETEROCYCLES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2017-01-26 | — | — | US | disclosed |
| WO-2015150564-A1 | SUBSTITUTED FUSED HETEROCYCLES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2015-10-08 | — | — | WO | disclosed |
| US-8598163-B2 | Derivatives of [1,3]Oxazin-2-one useful for the treatment of metabolic diseases such as lipid disorders | VITAE PHARMACEUTICALS, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2393813-B1 | Cyclic inhibitors of 11 ß-hydroxysteroid dehydrogenase 1 useful for the treatment of diseases related to elevated level of cortisol | VITAE PHARMACEUTICALS INC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20120040973-A1 | DERIVATIVES OF [1,3]OXAZIN-2-ONE USEFUL FOR THE TREATMENT OF METABOLIC DISEASES SUCH AS LIPID DISORDERS | VITAE PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2393813-A2 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010091067-A2 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040973-A1 | DERIVATIVES OF [1,3]OXAZIN-2-ONE USEFUL FOR THE TREATMENT OF METABOLIC DISEASES SUCH AS LIPID DISORDERS | HSD11B1, HSD11B2, HSD17B1 | RAPGEF4 4664/4885F2 4466/4885PRSS1 715/4885 |
| US-20190152977-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | PRKACA, PRKDC, PRKACB | RAPGEF4 972/4885F2 3966/4885PRSS1 1155/4885 |
| US-10683297-B2 | Substituted heteroaryl compounds and methods of use | PRKACA, PRKDC, PRKACB | RAPGEF4 972/4885F2 3966/4885PRSS1 1155/4885 |
| US-20170022198-A1 | SUBSTITUTED FUSED HETEROCYCLES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | GPR119, GPR65, GPR88 | RAPGEF4 1302/4885F2 3972/4885PRSS1 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.